Cardiovascular Medicines · LP-051
Enalapril Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-051Cardiovascular Medicines
- Generic identity
- EnalaprilTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-051
- Generic identity
- Enalapril
- Presentation
- Tablet
- Catalogue strength
- 5 mg; 10 mg; 20 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Enalapril.
- Dosage form: tablet.
- Catalogue strength / concentration: 5 mg; 10 mg; 20 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Cardiovascular Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Exact enalapril chemical form/strength basis, score/divisibility and formulation for each strength.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
| B | 10 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
| C | 20 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Enalapril is an angiotensin-converting enzyme inhibitor used in selected blood-pressure and heart-failure management plans. It influences the renin–angiotensin system, with effects on blood pressure, kidney function and potassium. Ongoing monitoring may be necessary. This ingredient-level educational profile is not Luang Pharma approved product information, does not identify a suitable starting strength and does not establish that a particular patient should receive an ACE inhibitor.
Clinical context and therapeutic role
The clinician reviews the cardiovascular diagnosis, baseline renal function, potassium and other treatments. Heart-failure care and uncomplicated hypertension involve different decisions, even when the same ingredient is considered. Previous angioedema, pregnancy potential and episodes of dehydration are important factors. Follow-up should assess symptoms and laboratory findings where indicated. Persistent cough may be medicine-related, but chest pain or substantial breathlessness requires a clinical assessment rather than automatic attribution to an adverse effect.
Selected safety context
Angioedema can involve the tongue or airway and needs emergency care. High potassium, worsening renal function and excessive hypotension are other major concerns. A dry cough and dizziness can occur. Pregnancy is a significant contraindication concern because ACE inhibitors can harm the fetus. Potassium supplements, certain diuretics, NSAIDs and lithium need medication review. Markedly reduced urine, collapse, jaundice or severe allergy warrants urgent assessment. Any treatment change should account for the full clinical plan.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified clinician should review the cardiovascular indication, blood pressure or pulse where relevant, organ function and interacting medicines. Monitoring and treatment changes must be linked to the individual care plan and the authorized product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: EnalaprilArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-051.
Professional enquiries
Request product-specific evidence for LP-051.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.